| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(05)70101-7 |
| P698 | PubMed publication ID | 15863374 |
| P50 | author | Finn Egil Skjeldestad | Q64990557 |
| Cosette M Wheeler | Q87723651 | ||
| Kathrin Jansen | Q92382877 | ||
| Laura Koutsky | Q111548098 | ||
| P2093 | author name string | Lisa Lupinacci | |
| Mark H Stoler | |||
| Anna R Giuliano | |||
| Luisa L Villa | |||
| Alex Ferenczy | |||
| Heather L Sings | |||
| Brigitte M Ronnett | |||
| Matti Lehtinen | |||
| Darron R Brown | |||
| Robert J Kurman | |||
| Kevin A Ault | |||
| Mark T Esser | |||
| Diane M Harper | |||
| Frank J Taddeo | |||
| Eliav Barr | |||
| Radha Railkar | |||
| Jimmy Yu | |||
| Alfred J Saah | |||
| Carlos A Petta | |||
| Christian Malm | |||
| Gretchen M Tamms | |||
| Margareta Steinwall | |||
| Ronaldo L R Costa | |||
| Rosires P Andrade | |||
| Sven-Eric Olsson | |||
| P2860 | cites work | Sexual behaviour in Britain: early heterosexual experience | Q28210442 |
| Classification of papillomaviruses | Q29618731 | ||
| Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study | Q30307042 | ||
| Treatment for cervical intraepithelial neoplasia and risk of preterm delivery | Q31057677 | ||
| The 2001 Bethesda System: terminology for reporting results of cervical cytology | Q34124761 | ||
| 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities | Q34124766 | ||
| The cervical cancer epidemic that screening has prevented in the UK. | Q34334371 | ||
| Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine | Q34343006 | ||
| Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. | Q34505761 | ||
| Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay | Q34579346 | ||
| Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture | Q39420501 | ||
| Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies | Q41172103 | ||
| A controlled trial of a human papillomavirus type 16 vaccine | Q44366335 | ||
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
| Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women | Q45616224 | ||
| Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine | Q45616291 | ||
| Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer | Q45735319 | ||
| Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast | Q45759645 | ||
| Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. | Q45767220 | ||
| The health care costs of cervical human papillomavirus--related disease. | Q50747240 | ||
| Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours | Q57586552 | ||
| An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle | Q77569226 | ||
| A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine | Q80421986 | ||
| P433 | issue | 5 | |
| P921 | main subject | vaccine | Q134808 |
| placebo | Q269829 | ||
| multicenter clinical trial | Q6934595 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 271-278 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | |
| P478 | volume | 6 |
| Q38931001 | 15 years of The Lancet Oncology |
| Q49687633 | 9-Valent human papillomavirus vaccine: a review of the clinical development program |
| Q36244253 | A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1. |
| Q37521892 | A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France |
| Q33514126 | A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females |
| Q40238745 | A deletion and point mutation study of the human papillomavirus type 16 major capsid gene |
| Q39035319 | A metabolomics investigation into the effects of HIV protease inhibitors on HPV16 E6 expressing cervical carcinoma cells |
| Q33776653 | A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China. |
| Q51356513 | A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China. |
| Q35599310 | A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection |
| Q36822935 | A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). |
| Q40522671 | A paper-based immunoassay to determine HPV vaccination status at the point-of-care |
| Q37604412 | A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. |
| Q46564278 | A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. |
| Q37315930 | A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. |
| Q34701904 | A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study |
| Q33273063 | A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent |
| Q41524569 | A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity |
| Q36534239 | Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis |
| Q35927665 | Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice |
| Q59329445 | Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus |
| Q36773460 | Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing |
| Q40340447 | Adverse effects of the human papillomavirus vaccine |
| Q37164836 | Age considerations when vaccinating against HPV. |
| Q37222480 | Age for HPV vaccination |
| Q47951363 | Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. |
| Q33260497 | Alternative technologies in cervical cancer screening: a randomised evaluation trial |
| Q37157589 | American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment |
| Q34001838 | An armamentarium of wart treatments |
| Q36468756 | An overview of viral oncology in Italy - report from the Pavia meeting on solid tumors |
| Q36971738 | Anal cancer and human papillomaviruses in heterosexual men. |
| Q37466363 | Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland |
| Q39926013 | Annual disease burden due to human papillomavirus 16 and 18 infections in Finland |
| Q50791218 | Annual productivity costs due to cervical cancer mortality in the United States. |
| Q36952972 | Answering human papillomavirus vaccine concerns; a matter of science and time |
| Q34054306 | Antibody detection in tear samples as a surrogate to monitor host immunity against papillomavirus infections in vaccinated and naturally infected hosts |
| Q35501007 | Applications of viral nanoparticles in medicine. |
| Q26783973 | Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV |
| Q27692056 | Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world? |
| Q44046271 | Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands |
| Q37715865 | Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program |
| Q33716047 | Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa |
| Q35203345 | Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with men |
| Q36921606 | Association of HPV types 6, 11, 16, and 18 DNA detection and serological response in unvaccinated adolescent women |
| Q92842963 | B-cell restriction - an alternative piece to the puzzle |
| Q34677865 | Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil |
| Q38700357 | Behavioral abnormalities in young female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil |
| Q43703293 | Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong. |
| Q38111597 | Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. |
| Q37802641 | Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine |
| Q34641651 | Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58. |
| Q36088309 | Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles |
| Q37896455 | Bio-inspired, bioengineered and biomimetic drug delivery carriers |
| Q38538490 | Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare |
| Q38198822 | Bovine Papillomavirus: New Insights into an Old Disease |
| Q37219752 | Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. |
| Q81583241 | Brachial plexus neuritis following HPV vaccination |
| Q34064413 | Branched-linear and agglomerate protein polymers as vaccine platforms |
| Q34118631 | Brief report: Measuring the attitudes of health care professionals in Dane County toward adolescent immunization with HPV vaccine. |
| Q88336925 | CHAPTER 5 HPV infection and HPV-associated neoplasia in immunocompromised women |
| Q56959393 | CHAPTER 8 HPV vaccines |
| Q88336927 | CHAPTER 9 Delivering HPV vaccine in the industrial and developing world: the role of the ob-gyn community |
| Q91746479 | Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study |
| Q46928416 | Cancer in populations of African Ancestry: studies of the African Caribbean Cancer Consortium |
| Q36554683 | Cancer vaccines: a clinical perspective |
| Q81417332 | Cancer vaccines: on the threshold of success |
| Q28743261 | Capsomer vaccines protect mice from vaginal challenge with human papillomavirus |
| Q64912100 | Case of Paradoxical Cultural Sensitivity: Mixed Method Study of Web-Based Health Informational Materials About the Human Papillomavirus Vaccine in Israel. |
| Q28282622 | Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors |
| Q38242083 | Cell-mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination |
| Q80204276 | Cell-mediated immune responses to COPV early proteins |
| Q37350422 | Cellular and molecular biological aspects of cervical intraepithelial neoplasia |
| Q44399396 | Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles |
| Q45407070 | Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer |
| Q47291087 | Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types |
| Q26851311 | Cervical Cancer |
| Q84595950 | Cervical cancer |
| Q93501248 | Cervical cancer |
| Q26851681 | Cervical cancer control for Hispanic women in Texas: strategies from research and practice |
| Q36064395 | Cervical cancer in India and HPV vaccination |
| Q36595677 | Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists |
| Q46989685 | Cervical cancer prevention: new opportunities for primary and secondary prevention in the 21st century |
| Q36839786 | Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination |
| Q81542013 | Cervical cancer vaccination indications, efficacy, and side effects |
| Q82009235 | Cervical cancer vaccination: the real meaning of cross-protection and its impact on the prevention |
| Q80383106 | Cervical cancer vaccines available in 2007 |
| Q42582614 | Cervical cancer, human papillomavirus, and vaccination |
| Q50785774 | Cervical cancer: a call for political will. |
| Q36584350 | Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. |
| Q36584357 | Chapter 13: Current findings from prophylactic HPV vaccine trials |
| Q36584367 | Chapter 16: HPV vaccines in immunocompromised women and men. |
| Q36537615 | Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination |
| Q36584383 | Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays--an update |
| Q30230410 | Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries |
| Q36584407 | Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts |
| Q36584416 | Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease |
| Q36632749 | Characterisation of human papillomavirus (HPV) genotypes in the Azorean population, Terceira island. |
| Q35857294 | Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. |
| Q42278244 | Characterization of human papillomavirus by capillary isoelectric focusing with whole-column imaging detection |
| Q35079915 | Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. |
| Q38070958 | Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials |
| Q36155443 | Childhood immunisation: what is the future? |
| Q37356046 | Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines |
| Q35656638 | Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia |
| Q37848402 | Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer |
| Q36578289 | Clinical utility of HPV genotyping |
| Q58791545 | Co-delivery of a CD4 T cell helper epitope via covalent liposome attachment with a surface-arrayed B cell target antigen fosters higher affinity antibody responses |
| Q35918834 | Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years |
| Q36256554 | Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). |
| Q37320896 | Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination |
| Q35066675 | Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay |
| Q35784544 | Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica |
| Q45240887 | Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice |
| Q35918838 | Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years |
| Q37357526 | Consensus recommendations for cervical cancer prevention in the Czech Republic: a report of the International Conference on Human Papillomavirus in Human Pathology (Prague, 1-3 May 2008). |
| Q37371923 | Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization |
| Q35792707 | Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization |
| Q34365197 | Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study |
| Q34033823 | Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination |
| Q36765963 | Cost-effectiveness analyses of human papillomavirus vaccination |
| Q37321084 | Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia |
| Q33523171 | Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan |
| Q37009015 | Cost-effectiveness of human papillomavirus vaccination in the United States |
| Q54540012 | Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel. |
| Q64896768 | Cost-utility analysis of vaccination against HPV in Israel. |
| Q39023304 | Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features |
| Q48409281 | Curcumin as an anti-human papillomavirus and anti-cancer compound |
| Q26991640 | Current status of human papillomavirus vaccines |
| Q33665786 | DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women |
| Q39640508 | Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. |
| Q57079901 | Dendrimeric based microbicides against sexual transmitted infections associated to heparan sulfate |
| Q36681262 | Dendritic cells and vaccine design for sexually-transmitted diseases |
| Q34706815 | Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env. |
| Q54411999 | Detection and quantification of human papillomavirus genital infections: virological, epidemiological, and clinical applications |
| Q36567611 | Developing Michigan Cancer Foundation 7 Cells with Stable Expression of E7 Gene of Human Papillomavirus Type 16. |
| Q36731663 | Developing an HPV vaccine to prevent cervical cancer and genital warts |
| Q34786808 | Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection |
| Q37116707 | Development and evaluation of a liquid bead microarray assay for genotyping genital human papillomaviruses |
| Q90449507 | Development of Low-Cost Point-of-Care Technologies for Cervical Cancer Prevention Based on a Single-Board Computer |
| Q38948288 | Development of a Cost-Effective Educational Tool to Promote Acceptance of the HPV Vaccination by Hispanic Mothers |
| Q39173880 | Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs |
| Q43762357 | Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18. |
| Q30226559 | Difficulties in the prevention of cervical cancer: adults' attitudes towards HPV vaccination 3 years after introducing the vaccine in Hungary |
| Q40259578 | Display of HIV-1 Envelope Protein on Lambda Phage Scaffold as a Vaccine Platform. |
| Q52312756 | Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. |
| Q33777098 | Distribution of genital wart human papillomavirus genotypes in China: a multi-center study |
| Q34412349 | Distribution of high-risk human papillomavirus genotypes among HIV-negative women with and without cervical intraepithelial neoplasia in South Africa |
| Q34070356 | Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa |
| Q35647100 | Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? |
| Q33530945 | Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study |
| Q36496385 | EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge |
| Q39241147 | Ecological validity of cost-effectiveness models of universal HPV vaccination: A systematic literature review |
| Q37839828 | Economic evaluation of human papilloma virus vaccination in the European Union: a critical review |
| Q37763114 | Economic evaluations of human papillomavirus vaccines |
| Q40207173 | Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials |
| Q34210255 | Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data |
| Q36007989 | Effective strategies for HPV vaccine delivery: the views of pediatricians |
| Q34605012 | Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review |
| Q90689589 | Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men |
| Q33791312 | Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis |
| Q44634881 | Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials |
| Q24614644 | Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males |
| Q43427868 | Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years |
| Q37500742 | Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence |
| Q30372990 | Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. |
| Q36440493 | Emerging vaccines: evidence and considerations for practice integration. |
| Q39857919 | Enhanced papillomavirus-like particle production in insect cells |
| Q37735000 | Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females |
| Q28476101 | Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE) |
| Q39013219 | Enhancing efficacy and mucosa-tropic distribution of an oral HIV-PsV DNA vaccine in animal models |
| Q33284467 | Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa |
| Q37084482 | Ensuring access to HPV vaccines through integrated services: a reproductive health perspective |
| Q33488325 | Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model |
| Q21284469 | Epidemiology and natural history of human papillomavirus infections in the female genital tract |
| Q37399223 | Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. |
| Q21144710 | Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses |
| Q33652353 | Epidemiology of HPV in HIV-positive and HIV-negative fertile women in Cameroon, West Africa |
| Q45372662 | Epstein-Barr Virus and Human Papillomavirus Infection in Vulvar Lichen Sclerosus |
| Q35914337 | Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model |
| Q34437088 | Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model. |
| Q42286605 | Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. |
| Q36610489 | Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK |
| Q35944640 | Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection |
| Q37449937 | Estimation of utility weights for human papilloma virus-related health states according to disease severity. |
| Q37107029 | Evaluating a surrogate endpoint at three levels, with application to vaccine development |
| Q34986037 | Evaluating the impact of human papillomavirus vaccines |
| Q37256436 | Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening |
| Q35887646 | Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa |
| Q34038946 | Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women |
| Q36422593 | Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies |
| Q50084378 | Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up |
| Q37320899 | Evolution of the health economics of cervical cancer vaccination |
| Q36994672 | Evolutionary and biophysical relationships among the papillomavirus E2 proteins |
| Q39973023 | Expression of human papilloma virus type 16 antigens, specific targeting as well as formation of virus-like particles by HSV-1 amplicon vectors |
| Q40097092 | Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana |
| Q34154315 | Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle |
| Q34042304 | Factors influencing familial decision-making regarding human papillomavirus vaccination |
| Q44173679 | First-generation vaccines against human papillomavirus |
| Q38380284 | Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine |
| Q36088069 | Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck |
| Q36720912 | GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side |
| Q39178605 | Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran. |
| Q36532089 | Gene therapy in gynecological cancer |
| Q36684362 | Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention |
| Q36353396 | Genital human papillomavirus infection in men. |
| Q55383496 | Genotype I of Japanese Encephalitis Virus Virus-like Particles Elicit Sterilizing Immunity against Genotype I and III Viral Challenge in Swine. |
| Q22241238 | Global cancer statistics |
| Q37686631 | Glycyrrhiza uralensis water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine |
| Q37066141 | Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention |
| Q35635209 | HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein |
| Q37341642 | HPV Vaccination: Attitude and Knowledge among German Gynecologists |
| Q58271239 | HPV Vaccine Acceptance in a Clinic-based Sample of Women in the Rural South |
| Q36976268 | HPV Vaccines: today and in the Future |
| Q37581762 | HPV as a model for the development of prophylactic and therapeutic cancer vaccines. |
| Q34157209 | HPV catch-up vaccination of young women: a systematic review and meta-analysis |
| Q62660928 | HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy |
| Q58281383 | HPV in sub-Saharan Africa |
| Q33868453 | HPV knowledge, attitudes, and cultural beliefs among Hispanic men and women living on the Texas-Mexico border |
| Q36606596 | HPV type infection in different anogenital sites among HIV-positive Brazilian women |
| Q37135183 | HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee |
| Q36627269 | HPV vaccination with Gardasil: a breakthrough in women's health |
| Q37410888 | HPV vaccination: the beginning of the end of cervical cancer? - A Review. |
| Q38112976 | HPV vaccine cross-protection: Highlights on additional clinical benefit. |
| Q36998569 | HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. |
| Q48163957 | HPV vaccine promotion: does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior? |
| Q37687426 | HPV vaccine: Cervarix |
| Q40396965 | HPV-6 Molecular Variants Association With the Development of Genital Warts in Men: The HIM Study |
| Q38104391 | HPV-genotypes in high-grade intraepithelial cervical lesions in Danish women |
| Q30252655 | HPV-related external genital lesions among men residing in Brazil |
| Q36743674 | HPV-vaccination against cervical carcinoma: will it really work? |
| Q64377560 | HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice |
| Q34612818 | HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection |
| Q98881852 | HPVomics: An integrated resource for the human papillomavirus epitome and therapeutics |
| Q46755658 | Health beliefs and attitudes associated with HPV vaccine intention among young gay and bisexual men in the Southeastern United States. |
| Q45024333 | Health biotechnology innovation on a global stage |
| Q38873922 | Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings |
| Q44900620 | Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. |
| Q37771396 | Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options |
| Q36974618 | High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger |
| Q47599087 | High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in São Paulo, Brazil |
| Q36612475 | High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up |
| Q37063349 | High-risk and multiple human papillomavirus infections among married women in Can Tho, Viet Nam. |
| Q35073297 | Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. |
| Q25257230 | How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? |
| Q80167962 | How much cervical cancer in Australia is vaccine preventable? A meta-analysis |
| Q35235035 | How will HPV vaccines affect cervical cancer? |
| Q40068101 | Human Papilloma Virus vaccine for low and middle income countries: A step too soon? |
| Q39125435 | Human Papillomavirus Associated Cancers of the Head and Neck: An Australian Perspective. |
| Q34510438 | Human Papillomavirus in Brazilian women with and without cervical lesions |
| Q38105040 | Human Papillomavirus-mediated cervical cancer awareness and Gardasil vaccination: a pilot survey among North Indian women |
| Q36733146 | Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening |
| Q37422821 | Human papilloma virus (HPV) vaccination in childhood: challenges and perspectives |
| Q34029941 | Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? |
| Q36925107 | Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study |
| Q24657891 | Human papillomavirus and HPV vaccines: a review |
| Q45113373 | Human papillomavirus and cervical screening: misconceptions undermine adherence |
| Q37053303 | Human papillomavirus and vaccination in cervical cancer |
| Q38018120 | Human papillomavirus as a target for management, prevention and therapy |
| Q54518677 | Human papillomavirus detection and typification in cutaneous and mucosal lesions of HIV-seropositive patients. |
| Q47599014 | Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region |
| Q37321854 | Human papillomavirus disease and vaccines |
| Q34675079 | Human papillomavirus disease and vaccines in adolescents |
| Q34074074 | Human papillomavirus genotype distribution in Madrid and correlation with cytological data |
| Q40044496 | Human papillomavirus genotype distribution in cervical samples among vaccine naïve Barbados women |
| Q35209618 | Human papillomavirus genotype distribution in cervical samples collected in routine clinical practice at the Nantes University Hospital, France |
| Q43462309 | Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). |
| Q81365764 | Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study |
| Q46806693 | Human papillomavirus genotypes and phylogenetic analysis of HPV-16 variants in HIV-1 infected subjects in Italy |
| Q33638491 | Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe |
| Q37039593 | Human papillomavirus in cervical and head-and-neck cancer |
| Q44424336 | Human papillomavirus infection |
| Q33622107 | Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women |
| Q46135972 | Human papillomavirus infection and related cancers in sub-Saharan Africa: burden and tools for prevention |
| Q36612065 | Human papillomavirus infection: an anonymous prevalence study in South Wales, UK. |
| Q36480555 | Human papillomavirus infection: an old disease, a new vaccine |
| Q36742001 | Human papillomavirus infection: the role of vaccination in pediatric patients |
| Q36510632 | Human papillomavirus infections in primary care |
| Q35862810 | Human papillomavirus knowledge, vaccine acceptance, and vaccine series completion among female entertainment and sex workers in Phnom Penh, Cambodia: the Young Women's Health Study |
| Q42277972 | Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa |
| Q37010572 | Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study |
| Q36530204 | Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). |
| Q45189245 | Human papillomavirus testing for primary cervical cancer screening |
| Q36817148 | Human papillomavirus therapeutic vaccines in head and neck tumors |
| Q38089937 | Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. |
| Q60655522 | Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L |
| Q35028816 | Human papillomavirus types 52 and 58 are prevalent in uterine cervical squamous lesions from Japanese women |
| Q33572460 | Human papillomavirus vaccination in survivors of childhood cancer |
| Q26853556 | Human papillomavirus vaccination: a case study in translational science |
| Q35558593 | Human papillomavirus vaccination: current indications and future directions |
| Q37345134 | Human papillomavirus vaccine and cervical cancer prevention |
| Q79610384 | Human papillomavirus vaccine efficacy: aligning expectations with reality |
| Q82710054 | Human papillomavirus vaccine for children and adolescents |
| Q37455512 | Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio |
| Q57705981 | Human papillomavirus vaccine: What are women most concerned about? |
| Q35886746 | Human papillomavirus vaccine: a boon or curse |
| Q36764915 | Human papillomavirus vaccine: progress and the future |
| Q37346095 | Human papillomavirus vaccines and vaccine implementation |
| Q36690278 | Human papillomavirus vaccines for the treatment of cervical cancer |
| Q36280578 | Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented? |
| Q35944623 | Human papillomavirus vaccines launch a new era in cervical cancer prevention |
| Q80420441 | Human papillomavirus vaccines to prevent cervical cancer |
| Q38022478 | Human papillomavirus vaccines: where do they fit in HIV-infected individuals? |
| Q37226398 | Human papillomavirus, cervical cancer, and the vaccines |
| Q37363411 | Human papillomavirus--lessons from history and challenges for the future |
| Q51660581 | Human papillomavirus-related gynecologic neoplasms: screening and prevention. |
| Q38299511 | Human papillomavirus-related high-grade squamous intraepithelial lesions of the esophagus, skin, and cervix in an adolescent lung transplant recipient: a case report and literature review |
| Q36550902 | Human papillomaviruses and cervical cancer |
| Q36295220 | Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides |
| Q35532771 | Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody |
| Q33636333 | Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses. |
| Q24545868 | Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera |
| Q37419555 | Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins |
| Q43446049 | Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature |
| Q36283939 | Immune responses to human papillomavirus |
| Q81401502 | Immunization update |
| Q26777330 | Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease |
| Q37084984 | Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women |
| Q36916512 | Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease |
| Q42280340 | Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose |
| Q35739048 | Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old |
| Q83925050 | Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 |
| Q37239410 | Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis |
| Q36460849 | Immunostimulatory colloidal delivery systems for cancer vaccines. |
| Q37773267 | Immunotherapeutic polyoma and human papilloma virus-like particles |
| Q35049821 | Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses |
| Q34033763 | Immunotherapy for cervical cancer: Research status and clinical potential |
| Q39760748 | Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection |
| Q43655015 | Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women |
| Q34611400 | Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard |
| Q45404033 | Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine |
| Q38930996 | Influencing cancer treatment |
| Q37712999 | Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection |
| Q37279580 | Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation |
| Q36815006 | Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing |
| Q82456786 | Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels |
| Q28660843 | Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice |
| Q57089416 | Is HPV testing with cytological triage a more logical approach in cervical cancer screening? |
| Q33920755 | Is administration of the HPV vaccine during pregnancy feasible in the future? |
| Q24802323 | Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant |
| Q37382421 | Knowledge of HPV among United States Hispanic women: opportunities and challenges for cancer prevention |
| Q36197587 | Knowledge, Awareness and Attitude on HPV, HPV Vaccine and Cervical Cancer among the College Students in India |
| Q31131825 | Knowledge, attitude, practice and barriers on vaccination against human papillomavirus infection: a cross-sectional study among primary care physicians in Hong Kong |
| Q51542634 | Lack of effects on male fertility from a quadrivalent HPV vaccine in Sprague‐Dawley rats |
| Q94272324 | Le vaccin contre le virus du papillome humain pour les enfants et les adolescents |
| Q27013018 | Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins |
| Q36608673 | Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. |
| Q37386019 | Literature review of human papillomavirus vaccine acceptability among women over 26 years. |
| Q37425284 | Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials |
| Q37296790 | Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections |
| Q37359932 | Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine |
| Q54393225 | Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. |
| Q34045548 | Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses |
| Q37177750 | Major clinical research advances in gynecologic cancer 2008 |
| Q38178742 | Management of advanced or recurrent cervical cancer: chemotherapy and beyond |
| Q35205476 | Management strategies and cost effectiveness in the prevention of cervical cancer |
| Q91811288 | Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine |
| Q97526303 | Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches |
| Q36807320 | Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer |
| Q34049709 | Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. |
| Q37302509 | Model for assessing human papillomavirus vaccination strategies |
| Q45404942 | Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine |
| Q33233438 | Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications |
| Q36862117 | Molecular biology of cervical cancer |
| Q36627755 | Molecular biomarkers for cancer detection in blood and bodily fluids |
| Q37222471 | Monitoring HPV vaccination |
| Q37808256 | Monitoring of human papillomavirus vaccination. |
| Q43636904 | Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. |
| Q34075698 | Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination |
| Q35623752 | Multiple human papillomavirus infections and type competition in men |
| Q36574571 | Nanoparticle delivery systems in cancer vaccines. |
| Q37104199 | Nanotechnology in vaccine delivery |
| Q43605407 | Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region |
| Q36933073 | Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia |
| Q33156844 | New quadrivalent HPV vaccine developments |
| Q35946997 | Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines |
| Q34111736 | Novel antivirals inhibit early steps in HPV infection |
| Q36607397 | Novel methods to treat and prevent human papillomavirus infection |
| Q35689082 | Novel microsphere-based method for detection and typing of 46 mucosal human papillomavirus types |
| Q34569084 | Oncogenic human papillomavirus (HPV) type distribution and HPV type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk |
| Q35054754 | Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer |
| Q41705641 | Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme |
| Q33910699 | Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 |
| Q34576677 | Optimization of multimeric human papillomavirus L2 vaccines |
| Q40026216 | Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis |
| Q37821482 | Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience |
| Q34407889 | Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature |
| Q35804927 | Oropharyngeal Cancer Epidemic and Human Papillomavirus |
| Q95826489 | Overview of Cervical Cancer in the Developing World |
| Q36679714 | Overview of cervical cancer in the developing world. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer |
| Q34730892 | Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine |
| Q38638841 | PD-1/PD-L1 biology and immunotherapy in HPV-positive oral cancers |
| Q39861475 | Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma |
| Q57540128 | Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls |
| Q22255483 | Papillomavirus genome structure, expression, and post-transcriptional regulation |
| Q37208883 | Papillomaviruses--to vaccination and beyond |
| Q35166924 | Papillomaviruses: Viral evolution, cancer and evolutionary medicine |
| Q35258843 | Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer |
| Q43611354 | Parental attitudes to pre-pubertal HPV vaccination. |
| Q59397134 | Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention |
| Q34012647 | Penile cancer: epidemiology, pathogenesis and prevention |
| Q37776876 | Penile intraepithelial neoplasia and other premalignant lesions of the penis |
| Q33815779 | Perceived need of a parental decision aid for the HPV vaccine: content and format preferences |
| Q36677490 | Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia |
| Q33905022 | Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. |
| Q37134986 | Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease |
| Q80206650 | Perspectives of contemporary papillomavirus research |
| Q45090253 | Phylogeographic analysis of human papillomavirus 58. |
| Q43619123 | Physician Attitudes and Practice Toward Human Papillomavirus Vaccination |
| Q36888029 | Plant-derived virus-like particles as vaccines |
| Q34975090 | Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. |
| Q35659008 | Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women |
| Q81502452 | Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. |
| Q35610248 | Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France |
| Q47165338 | Practices regarding human Papillomavirus counseling and vaccination in head and neck cancer: a Canadian physician questionnaire |
| Q30409053 | Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer |
| Q35185992 | Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles |
| Q84012251 | Preliminary HPV vaccine results for women older than 25 years |
| Q51578981 | Prevalence and distribution of human papillomavirus findings in swab specimens from gynaecology clinics of the east coast of Spain. |
| Q60918621 | Prevalence and incidence of genital warts and cervical Human Papillomavirus infections in Nigerian women |
| Q37342414 | Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy |
| Q37353483 | Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination |
| Q45215935 | Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study |
| Q34572303 | Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign |
| Q45342236 | Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women |
| Q36541670 | Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma |
| Q45410590 | Prevalence of human papilloma virus infection in women in rural Ethiopia |
| Q35605295 | Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy |
| Q85097331 | Prevalence of low‐risk and high‐risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: An epidemiological observational study |
| Q34762053 | Prevention of cancer by prophylactic human papillomavirus vaccines |
| Q82698544 | Prevention of cervical cancer |
| Q34272071 | Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine |
| Q36571291 | Prevention strategies of cervical cancer in the HPV vaccine era. |
| Q37021701 | Prevention, diagnosis, and treatment of cervical cancer |
| Q26749285 | Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline |
| Q45812304 | Proceedings From the First Asia-Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN) Meeting |
| Q34315981 | Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells |
| Q35736570 | Production of recombinant VP1-derived virus-like particles from novel human polyomaviruses in yeast |
| Q37014047 | Progress and prospects for L2-based human papillomavirus vaccines |
| Q35919119 | Progress in the development of a cervical cancer vaccine. |
| Q36082663 | Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women |
| Q37259642 | Promising particle-based vaccines in cancer therapy. |
| Q80279628 | Prophylactic DNA immunization against multiple papillomavirus types |
| Q37241351 | Prophylactic HPV vaccines: new interventions for cancer control |
| Q47719291 | Prophylactic HPV vaccines: reducing the burden of HPV-related diseases |
| Q37658879 | Prophylactic HPV vaccines: the Finnish perspective |
| Q44356028 | Prophylactic and therapeutic HPV immunization |
| Q40153697 | Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection |
| Q24545449 | Prophylactic human papillomavirus vaccines |
| Q36899064 | Prophylactic human papillomavirus vaccines: potential for sea change |
| Q33292779 | Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials |
| Q54217505 | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. |
| Q37154142 | Prospects and prejudices of human papillomavirus vaccines in India |
| Q36314993 | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. |
| Q39536359 | Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease |
| Q36705407 | Public awareness of human papillomavirus. |
| Q36611037 | Public awareness that HPV is a risk factor for cervical cancer. |
| Q37818140 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women |
| Q38229304 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts |
| Q80136333 | Quadrivalent human papillomavirus recombinant vaccine |
| Q24600011 | Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future |
| Q38819439 | Recent advancements in combination subunit vaccine development |
| Q36647920 | Recent advances in human papillomavirus vaccines |
| Q36958000 | Recent advances in medical dermatology |
| Q39235934 | Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. |
| Q55982769 | Recurrent respiratory papillomatosis |
| Q79966767 | Recurrent respiratory papillomatosis |
| Q37762184 | Recurrent respiratory papillomatosis: an overview |
| Q37770376 | Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children |
| Q35592876 | Recurrent respiratory papillomatosis: current and future perspectives |
| Q38566309 | Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art |
| Q34863221 | Reducing the health burden of HPV infection through vaccination |
| Q92701833 | Reduction in HPV 16/18 prevalence among young women following HPV vaccine introduction in a highly vaccinated district, Japan, 2008-2017 |
| Q36176699 | Reduction of HPV infections through vaccination among at-risk urban adolescents |
| Q36375660 | Relationship between hWAPL polymorphisms and cervical cancer susceptibility |
| Q36716418 | Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. |
| Q35023935 | Results from a dose-response study using 3,3'-diindolylmethane in the K14-HPV16 transgenic mouse model: cervical histology |
| Q53266650 | Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. |
| Q37128123 | Review article: relationship of human papillomavirus with papillary squamous cell carcinoma of the upper aerodigestive tract: a review |
| Q36949778 | Review of Gardasil |
| Q38110696 | Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme |
| Q34686752 | Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer |
| Q80063979 | Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study |
| Q54216752 | Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus. |
| Q26799574 | Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus |
| Q37612161 | Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses |
| Q83704525 | Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females |
| Q40430523 | Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines |
| Q35558548 | Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults |
| Q37607430 | Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. |
| Q33162724 | Safety of human papillomavirus vaccines: a review. |
| Q45399287 | Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women |
| Q35121855 | Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence |
| Q39958594 | Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis |
| Q38668821 | Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. |
| Q51871486 | Seroepidemiology as basis for design of a human papillomavirus vaccination program. |
| Q33947813 | Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection |
| Q39975332 | Sexual behaviour in Ligurian (Northern Italy) adolescents and young people: suggestions for HPV vaccination policies. |
| Q80150272 | Sexually transmitted infections |
| Q37518473 | Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia |
| Q42323699 | Should routine neonatal circumcision be a policy to prevent penile cancer? | Opinion: No. |
| Q35220805 | Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology |
| Q34173407 | Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature |
| Q51873186 | Speculation overinflates long-term efficacy of vaccine for anal dysplasia. |
| Q33907700 | Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection |
| Q37937705 | Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women |
| Q36609838 | Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q37942643 | Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine |
| Q43452461 | Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years |
| Q28236008 | Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial |
| Q35111092 | Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure |
| Q40776057 | Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development. |
| Q36440502 | The HPV vaccine: an analysis of the FUTURE II study. |
| Q57028715 | The Impact of HPV as an Etiological Factor in Gynecological and Oropharyngeal Cancer |
| Q21129302 | The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies |
| Q46650971 | The acceptability of HPV vaccination among women attending the University of Saskatchewan Student Health Services |
| Q51727827 | The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. |
| Q37522123 | The challenge of eliminating cervical cancer in the United States: a story of politics, prudishness, and prevention |
| Q26770871 | The clinical development process for a novel preventive vaccine: An overview |
| Q50857612 | The combination of Pleurotus ferulae water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine. |
| Q37993109 | The cost effectiveness of human papillomavirus vaccines: a systematic review |
| Q48617316 | The cost-effectiveness of male HPV vaccination in the United States |
| Q91818565 | The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis |
| Q34241823 | The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis |
| Q81702322 | The end for genital human papillomavirus infections? |
| Q39442569 | The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation |
| Q35805491 | The future of vaccines for cervical cancer |
| Q28278978 | The human papillomavirus vaccine in Canada |
| Q36871265 | The human papillomavirus vaccine: The promise of cervical cancer prevention |
| Q37135272 | The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model |
| Q36519190 | The implementation and acceptability of an HPV vaccination decision support system directed at both clinicians and families. |
| Q83304463 | The moral justification for a compulsory human papillomavirus vaccination program |
| Q81673065 | The new challenges in the prevention of cervical cancer |
| Q81284219 | The new era of cervical cancer prevention: HPV vaccination |
| Q37242289 | The pediatrician's role in preventing cervical cancer |
| Q50732766 | The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. |
| Q80462054 | The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada |
| Q33764155 | The quality of life of patients with genital warts: a qualitative study |
| Q92178995 | The situation of vaccines for the prevention of infections in adults: An opinion paper on the situation in Spain |
| Q35552912 | The transcription map of HPV11 in U2OS cells adequately reflects the initial and stable replication phases of the viral genome |
| Q24685892 | The viral etiology of AIDS-associated malignancies |
| Q40728648 | Therapeutic Cancer Vaccines |
| Q33936427 | Therapeutic HPV DNA vaccines |
| Q84504653 | Therapeutic HPV DNA vaccines |
| Q56937332 | Therapeutic human papillomavirus vaccines: current clinical trials and future directions |
| Q36572609 | Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas |
| Q47255618 | Therapeutic vaccines for high-risk HPV-associated diseases. |
| Q51500570 | Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. |
| Q80814801 | To vaccinate or to screen--is that the question? |
| Q36793117 | Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination |
| Q38170683 | Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa |
| Q37442424 | Understanding HPV disease and prevention: a guide for school nurses |
| Q33894441 | Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus |
| Q34402948 | Using financial incentives to increase initial uptake and completion of HPV vaccinations: protocol for a randomised controlled trial |
| Q28280059 | VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus |
| Q44245059 | Vaccinating against HPV: physicians' and medical students' point of view |
| Q36743080 | Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018 |
| Q58217995 | Vaccination against human papillomavirus: A baseline survey of Canadian clinicians’ knowledge, attitudes and beliefs |
| Q45029232 | Vaccination and the evolutionary ecology of human papillomavirus |
| Q38082568 | Vaccination strategies in patients with IBD. |
| Q34078674 | Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. |
| Q34054427 | Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection |
| Q40399200 | Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus |
| Q36897382 | Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. |
| Q36712817 | Vaccine delivery using nanoparticles. |
| Q36379269 | Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men. |
| Q36899058 | Vaccines against human papillomavirus: perspectives for controlling cervical cancer |
| Q37071155 | Vaccines for Chlamydia infections of the female genital tract |
| Q47604101 | Vaccines for cervical cancer |
| Q28299036 | Vaccines for tumour prevention |
| Q37792984 | Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design |
| Q34617331 | Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches. |
| Q37608311 | Virus-like particle vaccines and adjuvants: the HPV paradigm |
| Q38059059 | Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development |
| Q44201038 | Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. |
| Q37328475 | Virus-like particles for the prevention of human papillomavirus-associated malignancies |
| Q42265420 | Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice |
| Q24650772 | Virus-like particles production in green plants |
| Q36602264 | Virus-like particles: passport to immune recognition |
| Q33448263 | Warts (genital) |
| Q55054088 | Warts (genital). |
| Q40063734 | What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection |
| Q33578796 | Why do low-income minority parents choose human papillomavirus vaccination for their daughters? |
| Q51257523 | Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. |
| Q34455750 | Worsening disparities in HPV vaccine utilization among 19–26 year old women |
| Q80130954 | [Advances in cervical cancer prevention: HPV vaccines] |
| Q82970082 | [Anal HPV infections] |
| Q81501586 | [Cutaneous squamous cell carcinoma and human papillomavirus] |
| Q80275938 | [HPV vaccines. Prophylactic vaccines from virus-like particles] |
| Q43986168 | [Human papillomavirus and cervical neoplasia]. |
| Q81063786 | [Human papillomavirus vaccination: attitude to a consultation on a therapeutic novelty] |
| Q80319619 | [Humoral and cellular immune response in HPV vaccination] |
| Q95788212 | [Impact of prophylactic HPV vaccines on dermatology and venereology] |
| Q52903256 | [Prophylactic and therapeutic vaccines against human papilloma virus]. |
| Q79939143 | [Prophylactic vaccination against human papillomavirus] |
| Q81548102 | [Vaccination against the human papilloma virus. All that glitters is not gold] |
Search more.